Roberto Valli
Marianna Penzo- 1Department of Medicine and Surgery and Genomic Medicine Center, University of Insubria, Varese, Italy
- 2Department of Medical and Surgical Sciences and Center for Applied Biomedical Research (CRBA), Alma Mater Studiorum University of Bologna, Bologna, Italy
Editorial on the Research Topic
Inherited and acquired ribosomopathies: missing puzzle pieces
Ribosomopathies are human diseases arising from altered ribosome biogenesis and function. The first of these conditions was described over two decades ago [X-linked Dyskeratosis Congenita (Heiss et al., 1998)]; but since then, the list keeps growing (Venturi and Montanaro, 2020). Ribosome biogenesis is an extremely energy demanding and complex cellular process, involving the coordinated activity of hundreds of different factors (proteins and non-coding RNAs) to produce structurally and functionally competent ribosomes (Kressler et al., 2017). Inherited or acquired genetic alterations underpinning ribosomopathies may involve ribosomal proteins (RP) coding genes [e.g., Diamond-Blackfan anemia–DBA (Costa et al., 2020)], ribosome assembly factors [e.g., Schwachman-Diamond Syndrome - SDS (Thompson et al., 2022)] or proteins involved in rRNA modifications [e.g., X-linked Dyskeratosis Congenita–X-DC (Penzo and Montanaro, 2018)] or processing [e.g., Cartilage-Hair Hypoplasia–CHH (Thiel and Rauch, 2011)]. Interestingly, all inherited ribosomopathies, which by definition arise as a consequence of germline mutations, have common features that are recapitulated as defects in highly proliferating tissues. Although paradoxically, in each disease the ribosome production defect has tissue-specific instead of ubiquitous effects. Even more intriguingly, most of ribosomopathies share an increased cancer susceptibility compared to the general population. Even though these hallmarks of ribosomopathies have been known for several years, the connection between these two apparently opposite features remains unknown.
Somatic genetic alterations broadly affecting ribosome biogenesis, are nowadays well known for having an active role in the onset and/or development of multiple cancer types, which can, therefore, be defined as acquired ribosomopathies (Sulima et al., 2017). This is very well matched with the increased cancer risk for patients affected by inherited ribosomopathies suggesting that de-regulation of ribosome biogenesis and function may actively contribute to malignant transformation (Penzo et al., 2019).
The cause-effect connections between the genetic defects undermining ribosome biogenesis and the hypo- or hyper-proliferative features of ribosomopathies are for the most part, poorly understood.
With this Research Topic, we aimed at adding some new pieces to the puzzle of understanding ribosomopathies, with a particular focus on the genetic, molecular and cellular alterations which are at the heart of these diseases. In the past decade scientists have made great advances in the characterization of the pathogenesis for some of these inherited disorders (like, for instance, in the case of SDS) (Warren, 2018), but for some others the scientific community is still struggling to find a nexus between the genetic defect, the outcome on ribosomes, and the downstream tissue-specific phenotype (like in the case of CHH) (Thiel and Rauch, 2011). It is worth mentioning that the technical advances made in the past two decades are just starting to bear fruit. We refer, for instance, to the development of approaches useful to define how the alterations impact ribosomal composition, structure, or function, which are necessary to understand the impact of the genetic alterations. In this Research Topic, Barozzi et al. propose an overview of the low- and high-throughput techniques which have recently become available to analyze pseudouridylation at specific sites in rRNAs, ranging from LC-MS to cryo-electron microscopy, passing through NGS. As these authors state, the qualitative and quantitative determination of pseudouridines at specific sites is the necessary first step in the path of defining the role of these modifications in physiology and pathology, here including X-DC.
One of the main hurdles remains the availability of appropriate experimental models to address the mechanistic effects of altered ribosome biogenesis in the developing organism, where the consequences of translation insufficiency are time- and cell-type- specific (Norris et al., 2021). In the effort to overcome this hurdle, Piantanida et al. developed a new cellular model of DBA, a rare autosomal dominant ribosomopathy characterized by failure of erythropoiesis, skeletal anomalies and incremented risk of developing malignancies [reviewed in (Ulirsch et al., 2018)]. To date, over 20 causative genes are known, mainly coding for RPs and RPS19 is most frequently mutated (Ulirsch et al., 2018). The authors here focused on RPS26, which exhibits peculiar characteristics compared to other DBA relevant RPs. They generated a stable RPS26 knockdown in HUDEP-1 cells, to recapitulate the erythroid phenotypic pattern of DBA patients bearing RPS26 mutations. This model will be useful, in the near future, to deepen our knowledge of the DBA pathophysiology.
In addition to in vitro generated cellular models, the patients themselves are important sources of genetic and cellular material, necessary for the characterization and useful for disease modeling. In this Research Topic there are three different instances of the importance of studying patients. Cole et al. focused on DBA, studying a large family in which the phenotypic expression of DBA was highly variable, despite sharing the same RPS19 mutation. Two members of the family showed no obvious clinical manifestation, highlighting the importance of other genetic, epigenetic or environmental factors in determining the phenotype. Furthermore, the authors underscored the importance of implementing cancer surveillance even in individuals with clinically mild phenotypes, as well as the benefit of long-term follow-up to identify late complications.
Taha et al. focused on SDS, in which the major causative gene is SBDS alone or in conjunction with mutations in other genes (Morini et al., 2019). It has been proposed that the interstitial deletion of chromosome 20, del (20) (q), or somatic mutations in EIF6 gene in the bone marrow could play a rescue role in SDS (Tan et al., 2021). Taha et al. studied an SDS patient by Whole Exome Sequencing (WES), finding canonical SBDS mutations in association with germline EIF6 mutations, thus confirming the benign effects of EIF6 inactivating mutations in SDS patients.
Bacci et al., finally, adopted a WES approach on a cohort of pediatric patients affected with T cell Acute Lymphoblastic leukemia (T-ALL) to study the somatic mutations occurring in RPs, ribosome biogenesis factors and translation regulatory factors. In fact, there is evidence of altered ribosomes playing a role in driving the malignant transformation, for T-ALL as well as for other cancer types (Penzo et al., 2019). These authors found a novel mutation in RPL10, and linked it to translational impairment, further supporting the parallelism between inherited and acquired ribosomopathies.
Albeit known for many years, ribosomopathies are still poorly understood. The diversity and also the specificity of clinical manifestations in each of these diseases suggests that impaired ribosome biogenesis determines a range of effects based on the cellular context, underscoring once more the importance of having appropriate models to study these diseases.
The puzzle, unfortunately, is still far from being complete.
Author contributions
The authors equally contributed to the conceiving and writing of the manuscript.
Acknowledgments
MP wishes to warmly thank Prof. Kenneth B. Marcu, Prof. Lorenzo Montanaro, Dr. Daniela Pollutri and Dr. Lorenza Bacci for critical reading and discussion of the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Costa, L. D., Leblanc, T., and Mohandas, N. (2020). Diamond-Blackfan anemia. Blood 136 (11), 1262–1273. doi:10.1182/blood.2019000947
Heiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., et al. (1998). X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19 (1), 32–38. doi:10.1038/ng0598-32
Kressler, D., Hurt, E., and Baßler, J. (2017). A puzzle of life: Crafting ribosomal subunits. Trends Biochem. Sci. 42 (8), 640–654. doi:10.1016/j.tibs.2017.05.005
Morini, J., Nacci, L., Babini, G., Cesaro, S., Valli, R., Ottolenghi, A., et al. (2019). Whole exome sequencing discloses heterozygous variants in the DNAJC21 and EFL1 genes but not in SRP54 in 6 out of 16 patients with Shwachman-Diamond Syndrome carrying biallelic SBDS mutations. Br. J. Haematol. 185 (3), 627–630.
Norris, K., Hopes, T., and Aspden, J. L. (2021). Ribosome heterogeneity and specialization in development. Wiley Interdiscip. Rev. RNA 12 (4), e1644. doi:10.1002/wrna.1644
Penzo, M., Montanaro, L., Treré, D., and Derenzini, M. (2019). The ribosome biogenesis—cancer connection. Cells 8 (1), 55. doi:10.3390/cells8010055
Penzo, M., and Montanaro, L. (2018). Turning uridines around: Role of rRNA pseudouridylation in ribosome biogenesis and ribosomal function. Biomolecules 8 (2), 38. doi:10.3390/biom8020038
Sulima, S. O., Hofman, I. J. F., De Keersmaecker, K., and Dinman, J. D. (2017). How ribosomes translate cancer. Cancer Discov. 7 (10), 1069–1087. doi:10.1158/2159-8290.cd-17-0550
Tan, S., Kermasson, L., Hilcenko, C., Kargas, V., Traynor, D., Boukerrou, A. Z., et al. (2021). Somatic genetic rescue of a germline ribosome assembly defect. Nat. Commun. 12 (1), 5044. doi:10.1038/s41467-021-24999-5
Thiel, C. T., and Rauch, A. (2011). The molecular basis of the cartilage-hair hypoplasia-anauxetic dysplasia spectrum. Best. Pract. Res. Clin. Endocrinol. Metab. 25 (1), 131–142. doi:10.1016/j.beem.2010.08.004
Thompson, A. S., Giri, N., Gianferante, D. M., Jones, K., Savage, S. A., Alter, B. P., et al. (2022). Shwachman diamond syndrome: Narrow genotypic spectrum and variable clinical features. Pediatr. Res. 92 (6), 1671–1680. doi:10.1038/s41390-022-02009-8
Ulirsch, J. C., Verboon, J. M., Kazerounian, S., Guo, M. H., Yuan, D., Ludwig, L. S., et al. (2018). The genetic landscape of diamond-blackfan anemia. Am. J. Hum. Genet. 103 (6), 930–947. doi:10.1016/j.ajhg.2018.10.027
Venturi, G., and Montanaro, L. (2020). How altered ribosome production can cause or contribute to human disease: The spectrum of ribosomopathies. Cells 9 (10), 2300. doi:10.3390/cells9102300
Keywords: ribosome biogenesis, rare disease, ribosomopathy, RPL10, shwachman diamond syndrome, diamond blackfan anaemia, X-linked dyskeratosis congenita, T-ALL leukemia
Citation: Valli R and Penzo M (2023) Editorial: Inherited and acquired ribosomopathies: missing puzzle pieces. Front. Genet. 14:1194788. doi: 10.3389/fgene.2023.1194788
Received: 27 March 2023; Accepted: 03 April 2023;
Published: 12 April 2023.
Edited and reviewed by:
Jordi Pérez-Tur, Institute of Biomedicine of Valencia, Spanish National Research Council (CSIC), SpainCopyright © 2023 Valli and Penzo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Roberto Valli, roberto.valli@uninsubria.it; Marianna Penzo, marianna.penzo@unibo.it